VedaBio

VedaBio develops CRISPR-powered molecular detection platforms capable of ultra-rapid, amplification-free detection with massive multiplexing. Their CRISPR Cascade platform aims to deliver minutes-long results with high accuracy for multiple targets simultaneously.

The CRISPR Cascade platform uses engineered CRISPR enzymes to detect a nucleic acid target and then rapidly amplify the signal through a positive feedback loop, enabling amplification-free detection. It supports high multiplexing by pooling multiple targets within reactions and is designed for rapid reprogramming to new targets via sequence selection and optimization.

Who it’s for: Researchers and developers in molecular diagnostics, clinical laboratories, and biotechnology companies seeking rapid, highly multiplexed nucleic acid detection without target amplification.

press releases and strategic funding/partnerships indicated (Series A extension, partnerships with Siemens Healthineers; leadership appointments) – shows traction and funding activity